Message #13 From:
Stock News Bot Date: September 30, 2005 02:15:00 AM
MCDG News Molecular CEO Interview Scheduled for CEOcast
CHICAGO--(BUSINESS WIRE)--Sept. 30, 2005--Molecular Diagnostics, Inc. (OTCBB: MCDG) announces that CEO David Weissberg will be interviewed on CEOcast on Friday, October 7th at 11:00 a.m. Eastern time. In this interview, Dr. Weissberg intends to discuss the comprehensive changes that have taken place in Molecular in the last 30 days, and outline the plans that are underway to commercialize Molecular's product portfolio.
If you cannot listen to the interview, it will be available online at http://www.ceocast.com.
About Molecular Diagnostics, Inc.
Molecular Diagnostics develops cost-effective cancer screening systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, gastrointestinal, and other cancers. The InPath(TM) System is being developed to provide medical practitioners with a highly accurate, low-cost, cervical cancer screening system that can be integrated into existing medical models or at the point-of-care.
Certain statements in this release are forward-looking. These statements are based on Molecular Diagnostics' current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate Molecular Diagnostics' expectations with respect to the InPath(TM) System, and other factors set forth in reports and documents filed by Molecular Diagnostics with the Securities and Exchange Commission. Actual results may differ materially from Molecular Diagnostic's current expectations depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-KSB for the year ended December 31, 2004 and its Quarterly Reports on Form 10-QSB for the quarters ended March 31, 2005 and June 30, 2005. Except as expressly required by law, Molecular Diagnostics undertakes no obligation to publicly update or revise any forward-looking statements contained herein.
